keyword
MENU ▼
Read by QxMD icon Read
search

FDA Problems

keyword
https://www.readbyqxmd.com/read/28214789/-truth-in-research-labelling-regarding-wame-s-quoted-comments
#1
Margaret Winker
We were surprised to read Dr Noble's article, "Truth in research labelling". Dr Noble quotes from an email exchange he and I had regarding a petition that he had asked the World Association of Medical Editors (WAME) to endorse (personal communication, Bernard Carroll and John Noble, September 27, 2016). Unfortunately, the article's description of WAME's comments, which were intended to provide constructive suggestions to improve the petition by ensuring that it was fully supported by facts, is incomplete and the comments have been taken out of context...
February 13, 2017: Indian Journal of Medical Ethics
https://www.readbyqxmd.com/read/28194422/pharmacokinetic-properties-of-adenosine-amine-congener-in-cochlear-perilymph-after-systemic-administration
#2
Hao Chang, Ravindra S Telang, Sreevalsan Sreebhavan, Malcolm Tingle, Peter R Thorne, Srdjan M Vlajkovic
Noise-induced hearing loss (NIHL) is a global health problem affecting over 5% of the population worldwide. We have shown previously that acute noise-induced cochlear injury can be ameliorated by administration of drugs acting on adenosine receptors in the inner ear, and a selective A1 adenosine receptor agonist adenosine amine congener (ADAC) has emerged as a potentially effective treatment for cochlear injury and resulting hearing loss. This study investigated pharmacokinetic properties of ADAC in rat perilymph after systemic (intravenous) administration using a newly developed liquid chromatography-tandem mass spectrometry detection method...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28186948/patient-and-physician-attitudes-regarding-risk-and-benefit-in-streamlined-development-programmes-for-antibacterial-drugs-a-qualitative-analysis
#3
Thomas L Holland, Stephen Mikita, Diane Bloom, Jamie Roberts, Jonathan McCall, Deborah Collyar, Jonas Santiago, Rosemary Tiernan, Joseph Toerner
OBJECTIVES: To explore patient, caregiver and physician perceptions and attitudes regarding the balance of benefit and risk in using antibacterial drugs developed through streamlined development processes. DESIGN: Semistructured focus groups and in-depth interviews were conducted to elicit perceptions and attitudes about the use of antibacterial drugs to treat multidrug-resistant infections. Participants were given background information about antibiotic resistance, streamlined drug development programmes and FDA drug approval processes...
November 10, 2016: BMJ Open
https://www.readbyqxmd.com/read/28178410/strategies-to-extend-thrombolytic-time-window-for-ischemic-stroke-treatment-an-unmet-clinical-need
#4
REVIEW
Ike Dela Peña, Cesar Borlongan, Guofang Shen, Willie Davis
To date, reperfusion with tissue plasminogen activator (tPA) remains the gold standard treatment for ischemic stroke. However, when tPA is given beyond 4.5 hours of stroke onset, deleterious effects of the drug ensue, especially, hemorrhagic transformation (HT), which causes the most significant morbidity and mortality in stroke patients. An important clinical problem at hand is to develop strategies that will enhance the therapeutic time window for tPA therapy and reduce the adverse effects (especially HT) of delayed tPA treatment...
January 2017: Journal of Stroke
https://www.readbyqxmd.com/read/28169453/mechanical-properties-and-structure-function-relationships-of-human-chondrocyte-seeded-cartilage-constructs-after-in-vitro-culture
#5
Jill M Middendorf, Darvin J Griffin, Sonya Shortkroff, Caroline Dugopolski, Stephen Kennedy, Joseph Siemiatkoski, Itai Cohen, Lawrence J Bonassar
Autologous Chondrocyte Implantation (ACI) is a widely recognized method for the repair of focal cartilage defects. Despite the accepted use, problems with this technique still exist, including graft hypertrophy, damage to surrounding tissue by sutures, uneven cell distribution, and delamination. Modified ACI techniques overcome these challenges by seeding autologous chondrocytes onto a 3D scaffold and securing the graft into the defect. Many studies on these tissue engineered grafts have identified the compressive properties, but few have examined frictional and shear properties as suggested by FDA guidance...
February 7, 2017: Journal of Orthopaedic Research: Official Publication of the Orthopaedic Research Society
https://www.readbyqxmd.com/read/28165831/paxvax-cvd-103-hgr-single-dose-live-oral-cholera-vaccine
#6
Myron M Levine, Wilbur H Chen, James B Kaper, Michael Lock, Lisa Danzig, Marc Gurwith
Cholera remains a problem in developing countries and a risk for travelers. Hypochlorhydria, blood group O, cardiac and renal disease increase the risk of developing cholera gravis. Oral vaccines containing inactivated Vibrio cholerae and requiring two doses are available in some countries. No cholera vaccine had been available for U.S. travelers for decades until 2016 when CVD 103-HgR (Vaxchora™), an oral live attenuated vaccine, was licensed by the U.S. FDA. Areas covered: Enduring protection following wild-type cholera provided the rationale to develop a single-dose live oral vaccine...
February 6, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28165734/phantom-pains-problems-with-the-utility-of-alerts-for-pan-assay-interference-compounds
#7
Stephen Joseph Capuzzi, Eugene N Muratov, Alexander Tropsha
The use of substructural alerts to identify Pan-Assay INterference compoundS (PAINS) has become a common component of the triage process in biological screening campaigns. These alerts, however, were originally derived from a proprietary library tested in just six assays measuring protein-protein interaction (PPI) inhibition using the AlphaScreen detection technology only; moreover, 68% (328 out of the 480 alerts) were derived from four or fewer compounds. In an effort to assess the reliability of these alerts as indicators of pan-assay interference, we performed a large-scale analysis of the impact of PAINS alerts on compound promiscuity in bioassays using publicly available data in PubChem...
February 6, 2017: Journal of Chemical Information and Modeling
https://www.readbyqxmd.com/read/28164720/applications-of-computer-aided-approaches-in-the-development-of-hepatitis-c-antiviral-agents
#8
Aravindhan Ganesan, Khaled Barakat
Hepatitis C virus (HCV) is a global health problem that causes several chronic life-threatening liver diseases. The numbers of people affected by HCV are rising annually. Since 2011, the FDA has approved several anti-HCV drugs; while many other promising HCV drugs are currently in late clinical trials. Areas covered: This review discusses the applications of different computational approaches in HCV drug design. Expert opinion: Molecular docking and virtual screening approaches have emerged as a low-cost tool to screen large databases and identify potential small-molecule hits against HCV targets...
February 4, 2017: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/28163555/fda-flags-inconsistent-hospital-reporting-of-medical-device-problems-hazy-reporting-rules-beget-confusion
#9
Stephen Barlas
The National Evaluation System for Health Technology will be developed over the next five years to upgrade and improve the reporting of medical device adverse events. However, participants using the new system will incur significant capital costs.
February 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28137232/synthesis-properties-and-mechanism-of-action-of-new-generation-of-polycyclic-glycopeptide-antibiotics
#10
Eugenia N Olsufyeva, Anna N Tevyashova
The increased resistance of glycopeptide based antibiotics has become a serious problem for the chemotherapy of infections triggered by resistant Gram-positive bacteria. This has motivated the urgent sincere efforts to develop potent glycopeptide-based antibiotics in both academy and industry research laboratories. Understanding of the mechanism of action of natural and modified glycopeptides is considered as the basis for the rational design of compounds with valuable properties to achieve the fundamental results...
January 30, 2017: Current Topics in Medicinal Chemistry
https://www.readbyqxmd.com/read/28113166/knowing-what-you-eat-researchers-are-looking-for-ways-to-help-people-cope-with-food-allergies
#11
Kristina Grifantini
Food allergies and sensitivities have always been a public health problem but are becoming more prevalent worldwide. The U.S. Food and Drug Administration (FDA) reports that millions of Americans have allergic reactions to food each year. More than 17 million Europeans have a food allergy, and hospital admissions for severe reactions in children have risen sevenfold over the past decade, according to the European Academy of Allergy and Clinical Immunology.
September 2016: IEEE Pulse
https://www.readbyqxmd.com/read/28107783/lorcaserin-suppresses-oxycodone-self-administration-and-relapse-vulnerability-in-rats
#12
Harshini Neelakantan, Erica D Holliday, Robert G Fox, Sonja J Stutz, Sandra D Comer, Margaret Haney, Noelle C Anastasio, Frederick Gerard Moeller, Kathryn A Cunningham
Opioid use disorder (OUD) is a major public health problem. High relapse rates and poor treatment retention continue to pose major challenges in OUD treatment. Of the abused opioids, oxycodone is well described to maintain self-administration and evoke the durable conditioned responses ("cue reactivity") that result from pairing of opioid-related stimuli (e.g., paraphernalia) with repeated abuse. Serotonin (5-HT) neurotransmission, particularly through the 5-HT2C receptor (5-HT2CR), regulates psychostimulant reward and cue reactivity, and in the present experiments, we investigated the hypothesis that the selective 5-HT2CR agonist lorcaserin, which is FDA-approved for the treatment of obesity, will suppress oxycodone self-administration and oxycodone-associated cue reactivity in rats...
January 20, 2017: ACS Chemical Neuroscience
https://www.readbyqxmd.com/read/28051841/a-review-of-a-national-training-initiative-to-increase-provider-use-of-mat-to-address-the-opioid-epidemic
#13
REVIEW
Frances R Levin, Adam Bisaga, Maria A Sullivan, Arthur Robin Williams, Kathryn Cates-Wessel
BACKGROUND AND OBJECTIVES: The Providers' Clinical Support System for Medication Assisted Treatment (PCSS-MAT) initiative focuses on training and mentoring health professionals in the treatment of opioid use disorders (OUD) using pharmacological strategies. Led by the American Academy of Addiction Psychiatry (AAAP), PCSS-MAT is a consortium representing four of the five national professional organizations authorized by DATA 2,000-AAAP, American Osteopathic Academy of Addiction Medicine, American Psychiatric Association, and American Society of Addiction Medicine...
December 2016: American Journal on Addictions
https://www.readbyqxmd.com/read/28044943/forgotten-but-not-gone-new-developments-in-the-understanding-and-treatment-of-tardive-dyskinesia
#14
Jonathan M Meyer
The broad use of atypical antipsychotics was expected to dramatically reduce the prevalence and incidence of tardive dyskinesia (TD), but data show that TD remains an important challenge due the persistent nature of its symptoms and resistance to numerous treatment modalities, including antipsychotic discontinuation. Recent insights on genetic risk factors and new concepts surrounding pathophysiology have spurred interest in the possibility of targeted treatment for TD. As will be reviewed in this article, the number of evidence-based strategies for TD treatment is small: only clonazepam, amantadine, ginkgo biloba extract, and the vesicular monoamine transporter 2 (VMAT2) inhibitor tetrabenazine have compelling data...
December 2016: CNS Spectrums
https://www.readbyqxmd.com/read/28034999/perceptions-of-snus-among-us-adult-smokers-given-free-product
#15
Ellen Meier, Jessica L Burris, Amy Wahlquist, Elizabeth Garrett-Mayer, Kevin M Gray, Anthony J Alberg, K Michael Cummings, Matthew J Carpenter
INTRODUCTION: Snus uptake is nominal among US smokers. This longitudinal study examines a) perceptions of snus among US smokers given free snus for six weeks and b) a method for assessment of an alternative tobacco product at the population level. METHODS: Adult smokers (n=543; 69.2% female; Mage=49.3 years), uninterested in quitting, received free snus for ad libitum use. Based on their snus use during a 6-week sampling period, participants included: 1) never users (18...
December 29, 2016: Nicotine & Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco
https://www.readbyqxmd.com/read/27994475/isavuconazole-for-the-treatment-of-invasive-aspergillosis-and-mucormycosis-current-evidence-safety-efficacy-and-clinical-recommendations
#16
REVIEW
Suganthini Krishnan Natesan, Pranatharthi H Chandrasekar
The majority of invasive mold infections diagnosed in immunocompromised cancer patients include invasive aspergillosis (IA) and mucormycosis. Despite timely and effective therapy, mortality remains considerable. Antifungal agents currently available for the management of these serious infections include triazoles, polyenes, and echinocandins. Until recently, posaconazole has been the only triazole with a broad spectrum of anti-mold activity against both Aspergillus sp. and mucorales. Other clinically available triazoles voriconazole and itraconazole, with poor activity against mucorales, have significant drug interactions in addition to a side effect profile inherent for all triazoles...
2016: Infection and Drug Resistance
https://www.readbyqxmd.com/read/27983566/survey-of-the-huntington-s-disease-patient-and-caregiver-community-reveals-most-impactful-symptoms-and-treatment-needs
#17
Jennifer A Simpson, Debra Lovecky, Jane Kogan, Louise A Vetter, George J Yohrling
BACKGROUND: In preparation for a meeting with the U.S. Food and Drug Administration (FDA) on Patient-Focused Drug Development in Huntington's disease, the Huntington's Disease Society of America (HDSA) created and distributed two comprehensive surveys on the symptom experience and treatment approaches for Huntington's disease. OBJECTIVE: The objective of these surveys was to identify the specific symptoms that most impact the daily lives of individuals with Huntington's disease/Juvenile Huntington's disease (HD/JHD) and their caregivers and to solicit input on the types of treatments desired by HD affected families...
December 15, 2016: Journal of Huntington's Disease
https://www.readbyqxmd.com/read/27960557/the-biologics-of-ulcerative-colitis
#18
Fabio Salvatore Macaluso, Sara Renna, Ambrogio Orlando, Mario Cottone
Tumor necrosis factor α inhibitors dramatically changed the management of moderate-to-severe phenotypes of ulcerative colitis. The recent incoming of vedolizumab, which targets gut-specific leukocyte trafficking, provides a new biologic option for these patients. Areas covered: This review focuses on the rationale of use, efficacy, and safety profile of all biologics currently approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of ulcerative colitis, including tumor necrosis factor α inhibitors (Infliximab and biosimilars, adalimumab, and golimumab), and the more recent vedolizumab...
February 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27917682/the-preclinical-discovery-and-development-of-bortezomib-for-the-treatment-of-mantle-cell-lymphoma
#19
Richard Arkwright, Tri Minh Pham, Jeffrey A Zonder, Q Ping Dou
Mantle cell lymphoma (MCL) is an incurable, often aggressive B-cell malignancy. Bortezomib (BTZ), the 20S proteasome inhibitor was originally developed and approved for treatment of relapsed refractory multiple myeloma, and subsequently approved for treatment of MCL. BTZ's single-agent activity induces clinical responses in approximately one-third of relapsed MCL patients. BTZ-containing combination therapies have further improved the quality and duration of clinical responses compared to standard chemotherapies in previously untreated MCL patients...
December 20, 2016: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/27910713/sn-38-loading-capacity-of-hydrophobic-polymer-blend-nanoparticles-formulation-optimization-and-efficacy-evaluation
#20
Simona Dimchevska, Nikola Geskovski, Gjorgji Petruševski, Marina Chacorovska, Riste Popeski-Dimovski, Sonja Ugarkovic, Katerina Goracinova
One of the most important problems in nanoencapsulation of extremely hydrophobic drugs is poor drug loading due to rapid drug crystallization outside the polymer core. The effort to use nanoprecipitation, as a simple one-step procedure with good reproducibility and FDA approved polymers like Poly(lactic-co-glycolic acid) (PLGA) and Polycaprolactone (PCL), will only potentiate this issue. Considering that drug loading is one of the key defining characteristics, in this study we attempted to examine whether the nanoparticle (NP) core composed of two hydrophobic polymers will provide increased drug loading for 7-Ethyl-10-hydroxy-camptothecin (SN-38), relative to NPs prepared using individual polymers...
March 2017: Drug Development and Industrial Pharmacy
keyword
keyword
114371
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"